Abstract
Chemotherapy resistance remains a significant hurdle in breast cancer treatment, often driven by the persistence of cancer stem cells (CSCs). This study investigates the role of the polycomb group protein Bmi1 in mediating resistance to 5-Fluorouracil (5-Fu). We found that Bmi1 is significantly upregulated in 5-Fu-resistant and aggressive breast cancer cell lines. This overexpression correlates with an enrichment of the CD44+/CD24- CSC subpopulation. Mechanistically, Bmi1 expression is directly repressed by miR-200c and miR-203. Conversely, Bmi1 suppresses miR-200c expression through a p53-dependent pathway, creating a regulatory feedback loop. Knockdown of Bmi1 resensitizes resistant cells to 5-Fu by inducing mitochondrial apoptosis and reducing the CSC fraction, highlighting Bmi1 as a potential therapeutic target.
Introduction
The primary cause of treatment failure and disease relapse in breast cancer is the development of resistance to chemotherapeutic agents like 5-Fluorouracil (5-Fu). Emerging evidence suggests that a small population of cells, termed Cancer Stem Cells (CSCs), possesses intrinsic resistance mechanisms and the capacity for self-renewal. Bmi1, a key regulator of stem cell maintenance, has been implicated in various cancers, yet its specific contribution to breast cancer chemoresistance and its regulatory network involving microRNAs (miRNAs) required further elucidation.
Methods
The researchers employed several breast cancer cell models, including the sensitive MCF-7 line, its lab-derived 5-Fu resistant counterpart (MCF-7/5-Fu), and naturally aggressive lines (MDA-MB-231 and MDA-MB-453). To manipulate gene expression, shRNA was used for Bmi1 knockdown, while expression plasmids and synthetic miRNA mimics were used for overexpression. The physical interaction between miRNAs and the Bmi1 3’UTR was confirmed via luciferase reporter assays. Cellular phenotypes were assessed through flow cytometry (for CSC markers and apoptosis) and MTS assays to determine cell viability and IC50 values.
Results
Bmi1 Upregulation and Chemoresistance
Initial experiments revealed a strong correlation between Bmi1 levels and resistance to 5-Fu. Bmi1 protein and mRNA levels were markedly higher in the resistant MCF-7/5-Fu line and the aggressive MDA-MB-231 and MDA-MB-453 lines compared to the parental MCF-7 cells.
Functional Impact of Bmi1 on Cell Survival
To confirm Bmi1's role in resistance, the researchers modulated its expression. Overexpressing Bmi1 in sensitive MCF-7 cells increased their survival index when exposed to 5-Fu. Conversely, silencing Bmi1 in resistant cells (MCF-7/5-Fu/Sh) significantly enhanced their sensitivity to the drug, as evidenced by the downward shift in survival curves.
The miRNA-Bmi1-p53 Regulatory Loop
The study identified miR-200c and miR-203 as direct negative regulators of Bmi1. Luciferase assays showed that these miRNAs bind to the Bmi1 3’UTR, reducing its expression. Interestingly, a reciprocal relationship was discovered: Bmi1 suppresses miR-200c. This suppression is mediated by p53; Bmi1 downregulates p53, which is a known transcriptional activator of miR-200c. Restoring p53 expression was sufficient to reverse Bmi1-mediated miR-200c downregulation.
Discussion
This research maps a complex molecular cross-talk where Bmi1 promotes 5-Fu resistance by maintaining the CSC population and inhibiting apoptosis through the mitochondrial pathway. The discovery of the Bmi1-miRNA-p53 feedback loop provides a clearer picture of how cancer cells sustain high Bmi1 levels to evade treatment. While these in vitro findings are promising, further in vivo studies are necessary to validate Bmi1 inhibition as a viable clinical strategy. Targeting this regulatory axis could potentially overcome drug resistance and improve outcomes for breast cancer patients.
Summary updated